Quick Answer
NP Life Sciences Health Industry Group Inc. reported Cash and Equivalents of $70.6 thousand for fiscal year 2023.
NP Life Sciences Health Industry Group Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2023 | $70.6K | -42.1% |
| 2022 | $121.9K | +335.4% |
| 2021 | $28.0K | -76.4% |
| 2020 | $118.6K | -51.2% |
| 2019 | $242.9K | +121366.5% |
| 2018 | $200.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $84.6K | +1116.4% | -32.4% |
| June 30, 2023 | $125.1K | +21658.4% | -10.7% |
| March 31, 2023 | $140.1K | +505.8% | +15.0% |
| December 31, 2022 | $121.9K | +335.4% | +1653.1% |
| September 30, 2022 | $7.0K | -72.2% | +1108.9% |
| June 30, 2022 | $575.00 | -98.6% | -97.5% |
| March 31, 2022 | $23.1K | -74.1% | -17.4% |
| December 31, 2021 | $28.0K | -76.4% | +11.9% |
- NP Life Sciences Health Industry Group Inc. showed a decrease of -42.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2023 period, NP Life Sciences Health Industry Group Inc.’s cash and equivalents has grown by 35207.0% (from $200.00 to $70.6 thousand).
- The most recent figure is from NP Life Sciences Health Industry Group Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on April 16, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: